Related Experiment Video

Updated: Mar 9, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K

Complement receptor 1 gene polymorphisms are associated with cardiovascular risk

Marijke A de Vries1, Stella Trompet2, Simon P Mooijaart3

  • 1Department of Internal Medicine, Center for Diabetes and Vascular Medicine, Franciscus Gasthuis, Rotterdam, The Netherlands.

Atherosclerosis
|December 30, 2016
PubMed

Insights

Genetic variations in the complement receptor 1 (CR1) gene are linked to inflammation and coronary artery disease risk. This study analyzed CR1 gene polymorphisms in relation to cardiovascular events.

Area of Science:

  • Cardiovascular Genetics
  • Immunogenetics
  • Atherosclerosis Research

Background:

  • Inflammation is a critical factor in atherosclerosis development.
  • The complement system, including complement receptor 1 (CR1), is implicated in atherogenesis and immune complex clearance.
  • Existing evidence suggests a potential role for CR1 in cardiovascular disease (CVD).

Purpose of the Study:

  • To investigate the association between complement receptor 1 (CR1) gene single nucleotide polymorphisms (SNPs) and cardiovascular risk.
  • To explore the relationship between CR1 gene variations, inflammation markers, and incident coronary artery disease.

Main Methods:

  • Genotyping of 73 CR1 gene SNPs in 5244 elderly participants from the PROSPER study.
  • Logistic regression analysis adjusted for relevant covariates to assess SNP associations with cardiovascular disease.
  • Evaluation of associations between CR1 SNPs and serum C-reactive protein (CRP) levels.

Main Results:

  • Twelve of the 73 analyzed CR1 SNPs showed a significant association with the risk of myocardial infarction (fatal or nonfatal).
  • A significant global p-value (0.0489) rejected the null hypothesis of no associated SNPs.
  • Most SNPs associated with myocardial infarction risk were also linked to altered serum C-reactive protein (CRP) levels.

Conclusions:

  • Genetic variations within the CR1 gene are significantly associated with systemic inflammation.
  • CR1 gene polymorphisms are linked to an increased risk of incident coronary artery disease.
  • These findings highlight the role of CR1 in the interplay between genetic factors, inflammation, and cardiovascular health.
Abstract

Keywords:
Apolipoprotein BAtherosclerosisC-reactive proteinInflammationMyocardial infarction

More Related Videos

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.8K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
80
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
68
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
85
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K